← back to search

Charles F. Reynolds

University of Pittsburgh · US
Area of research
Pharmacology · Experimental and Cognitive Psychology
Research interest
Research interests include Treatment of Major Depression, Sleep and related disorders, Mental Health Treatment and Access, and Sleep and Wakefulness Research.
h-index
135
citations
108,572
works
1,192
NIH funding
primary concept
Medicine
email

Recent publications

Psychological intervention in individuals with subthreshold depression: individual participant data meta-analysis of treatment effects and moderators
The British Journal of Psychiatry 2025cited by 11position: middledoi
Sex differences in plasma proteomic markers in late-life depression
Psychiatry Research 2024cited by 12position: middledoi
Relationship between Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) total scores in older adults with major depressive disorder: An analysis of the OPTIMUM clinical trial
Journal of Affective Disorders 2024cited by 11position: middledoi
<scp>CYP2D6</scp> Phenotype Influences Pharmacokinetic Parameters of Venlafaxine: Results from a Population Pharmacokinetic Model in Older Adults with Depression
Clinical Pharmacology & Therapeutics 2024cited by 9position: middledoi
Randomized Clinical Trial of the Four Supports Intervention for Surrogate Decision-Makers in Intensive Care Units
American Journal of Respiratory and Critical Care Medicine 2024cited by 8position: middledoi
From Alert Child to Sleepy Adolescent: Age Trends in Chronotype, Social Jetlag, and Sleep Problems in Youth with Autism.
2024cited by 5position: contributordoi
CYP2D6 Phenotype Influences Pharmacokinetic Parameters of Venlafaxine: Results from a Population Pharmacokinetic Model in Older Adults with Depression.
2024cited by 3position: contributordoi
Depression is Associated with Treatment Response Trajectories in Adults with Prolonged Grief Disorder: A Machine Learning Analysis
2024cited by 1position: contributordoi
Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression
New England Journal of Medicine 2023cited by 72position: middledoi
Major depression, physical health and molecular senescence markers abnormalities
Nature Mental Health 2023cited by 27position: middledoi
Towards Outcome-Driven Patient Subgroups: A Machine Learning Analysis Across Six Depression Treatment Studies
American Journal of Geriatric Psychiatry 2023cited by 20position: middledoi
Life-Course Brain Health as a Determinant of Late-Life Mental Health: American Association for Geriatric Psychiatry Expert Panel Recommendations
American Journal of Geriatric Psychiatry 2023cited by 19position: middledoi
Change in patient‐centered outcomes of psychological well‐being, sleep, and suicidality following treatment with intravenous ketamine for late‐life treatment‐resistant depression
International Journal of Geriatric Psychiatry 2023cited by 13position: middledoi
Mental health care for older adults: recent advances and new directions in clinical practice and research
World Psychiatry 2022cited by 382position: firstdoi
Association of 24-Hour Activity Pattern Phenotypes With Depression Symptoms and Cognitive Performance in Aging
JAMA Psychiatry 2022cited by 94position: middledoi
Late-Life Depression is Associated With Increased Levels of GDF-15, a Pro-Aging Mitokine
American Journal of Geriatric Psychiatry 2022cited by 42position: middledoi
Association of Molecular Senescence Markers in Late-Life Depression With Clinical Characteristics and Treatment Outcome
JAMA Network Open 2022cited by 32position: middledoi
Intravenous Ketamine for Late-Life Treatment-Resistant Depression: A Pilot Study of Tolerability, Safety, Clinical Benefits, and Effect on Cognition
American Journal of Geriatric Psychiatry 2022cited by 30position: middledoi
Falls prediction using the nursing home minimum dataset
Journal of the American Medical Informatics Association 2022cited by 14position: middledoi
Venlafaxine XR treatment for older patients with major depressive disorder: decision trees for when to change treatment
Evidence-Based Mental Health 2022cited by 11position: middledoi
Predicting Medication Nonadherence in Older Adults With Difficult-to-Treat Depression in the IRL-GRey Randomized Controlled Trial
American Journal of Geriatric Psychiatry 2022cited by 8position: middledoi
Diversify Your Emotional Assets: The Association Between the Variety of Sources of Emotional Support and Thoughts of Death or Self-harm Among US Older Adults.
2022cited by 2position: contributordoi
Identifying the Common Genetic Basis of Antidepressant Response
Biological Psychiatry Global Open Science 2021cited by 130position: middledoi
Universal depression prevention: An umbrella review of meta-analyses
Journal of Psychiatric Research 2021cited by 40position: middledoi
The Effects of Gait Speed and Psychomotor Speed on Risk for Depression and Anxiety in Older Adults with Medical Comorbidities
Journal of the American Geriatrics Society 2021cited by 27position: middledoi
Low-Dose Augmentation With Buprenorphine for Treatment-Resistant Depression: A Multisite Randomized Controlled Trial With Multimodal Assessment of Target Engagement
Biological Psychiatry Global Open Science 2021cited by 12position: middledoi
Older Adults and the Mental Health Effects of COVID-19
JAMA 2020cited by 526position: lastdoi
A Brain Capital Grand Strategy: toward economic reimagination
Molecular Psychiatry 2020cited by 74position: middledoi
Pharmacogenetic Implications for Antidepressant Pharmacotherapy in Late-Life Depression: A Systematic Review of the Literature for Response, Pharmacokinetics and Adverse Drug Reactions
American Journal of Geriatric Psychiatry 2020cited by 38position: middledoi
Post-Intensive Care Unit Care. A Qualitative Analysis of Patient Priorities and Implications for Redesign.
2020cited by 18position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

Jordan F. Karp · University of Arizona15 papers (2021–2024)Benoit H. Mulsant · Canada Research Chairs15 papers (2020–2024)Eric J. Lenze · New York University14 papers (2020–2024)Daniel M. Blumberger · Centre for Addiction and Mental Health10 papers (2021–2024)Meryl A. Butters · University of Pittsburgh9 papers (2013–2024) · 8 papers (2019–2024)Helen Lavretsky · VA Greater Los Angeles Healthcare System5 papers (2020–2024)Breno S. Diniz · University of Exeter5 papers (2013–2024)Érica Leandro Marciano Vieira · The University of Texas Health Science Center at Houston4 papers (2022–2024)Patrick J. Brown · Columbia University4 papers (2022–2024)Steven P. Roose · Columbia University4 papers (2022–2024)Alastair J. Flint · University of Birmingham4 papers (2022–2024)George C. Tseng · University of Pittsburgh4 papers (2022–2024) · 4 papers (2022–2023)Ana Paula Mendes‐Silva · Centre for Addiction and Mental Health4 papers (2022–2024)Robert M. Arnold · UPMC Health System3 papers (2018–2024) · 3 papers (2018–2024)Steven M. Albert · University of Pittsburgh3 papers (2013–2022)Hanadi Ajam Oughli · University of California, Los Angeles3 papers (2022–2023)Douglas B. White · Brigham and Women's Hospital3 papers (2018–2024)